Mostrando 9 resultados de: 9
Filtros aplicados
Publisher
Pharmacogenomics(2)
Drug Metabolism and Drug Interactions(1)
Drug Metabolism and Personalized Therapy(1)
Expert Review of Clinical Pharmacology(1)
Neurologia(1)
Carbamazepine adverse drug reactions
ReviewAbstract: Introduction: Carbamazepine (CBZ) is used for the treatment of epilepsy and other neurological and pPalabras claves:adverse drug reactions, carbamazepine, Hepatotoxicity, Hypersensitivity, hyponatremia, Stevens-Johnson syndrome, Teratogenesis, toxic epidermal necrolysisAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusAn International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
ReviewAbstract: This international guideline proposes improving clozapine package inserts worldwide by using ancestrPalabras claves:American continental ancestry group, Asian continental ancestry group, clozapine/adverse effects, clozapine/blood, clozapine/metabolism, clozapine/therapeutic use, clozapine/toxicity, CYP1A2, drug labeling, European continental ancestry group, infection, inflammation, mortality/drug effects, Native, Sex, smoking.Autores:Adebayo R.A., Adrián LLerena, Anll Yaǧcloǧlu A.E., Arrojo-Romero M., Ayub M., Baptista T., Bebawi E., Bhattacharya R., Bilbily J., Bonelli R.M., Bousman C.A., Buckley P.F., Celofiga A., Chan S.K.W., Chopra N., Cohen D., Cotes R.O., Crespo-Facorro B., Cubała W.J., De Berardis D., De Las Cuevas C., De Leon J., Decloedt E., Eap C.B., Elkis H., Ertuǧrul A., Every-Palmer S., Farooq S., Fernandez-Egea E., Fountoulakis K.N., González-Esquivel D.F., Grover S., Gründer G., Hiemke C., Iglesias-Alonso A., Iglesias-Garcia C., Ignjatovic Ristic D., Jung-Cook H., Kaithi A.R., Kane J.M., Kelly D.L., Kim S.H., Kim Y.S., Kirilochev O.O., Kopeček M., Lana F., Lane H.Y., Lazary J., Leung J.G., Lin S.K., López-Jaramillo C., Marder S.R., Masmoudi R., McCollum B., McGrane I., Mohd Saffian S., Molden E., Motuca M., Ng C.H., Nielsen J., Olmos I., Ortiz B.B., Otsuka Y., Ouanes S., Pacheco Palha A.J., Pedro M.R., Procyshyn R.M., Quiles C., Rǎdulescu F., Rajkumar A.P., Ricciardi C., Rohde C., Ruan C.J., Sagud M., Sanz E.J., Schoretsanitis G., Schulte P.F.J., Seifritz E., Seppälä N., Shelton C., Silva A., Siskind D., Smith R.L., Solismaa A., Soloviev A., Spina E., Švancer P., Takeuchi H., Tang Y.L., Temmingh H., Torres R., Tsukahara M., Verdoux H., Villagrán-Moreno J.M., Wang C.Y., Wang G., Weizman A., Wilkowska A., Yecora A., Zolezzi M.Fuentes:scopusInfluence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
ArticleAbstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variabilityPalabras claves:Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusInterethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)
ReviewAbstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico'sPalabras claves:drug metabolizing enzymes, drug receptors, drug transporters, Mexicans, pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusPharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America
Conference ObjectAbstract: Congress of Pharmacogenetics and Personalized Medicine. Ethnicity, clinical implementation and regulPalabras claves:clinical trials, Latin American populations, metabolic genotypes, Metabolic phenotypes, native populations, pharmacogenetics, pharmacovigilanceAutores:Adrián LLerena, Altamirano C., Céspedes-Garro C., Enrique Terán, Francisco J.López Hernández, Galaviz-Hernandez C., Humberto Fariñas, Jung-Cook H., López-López M., MARTHA FORS, Martha M. Fors-López, Moya G.E., Ramirez R., Remírez D., Sosa-Macías M.G., Tarazona-Santos E.M., William F. WatersFuentes:googlescopusPharmacogenetics of adverse reactions to antiepileptic drugs
OtherAbstract: Introduction: Adverse drug reactions (ADRs) are a major public health concern and a leading cause ofPalabras claves:ABCC2, adverse drug reactions, Antiepileptic drugs, CYP2C9, human leukocyte antigen (HLA), pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusPharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine
ReviewAbstract: Patients treated with antiepileptic drugs can exhibit large interindividual variability in clinicalPalabras claves:antiepileptic drug, Cytochrome p450, lamotrigine, pharmacogenetics, Phenytoin, UDP-glucuronosyltransferase (UGT)Autores:Adrián LLerena, Dorado P., ElisaAlonso M., Jung-Cook H., López M.L., Machín E., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Penãs-Lledó E.M.Fuentes:googlescopusRelevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
ArticleAbstract: Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SCPalabras claves:ABCC2, carbamazepine, EPHX1, Epilepsy, NR1I2, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopus